WebJun 1, 2024 · Bivalirudin as a Systemic Anticoagulant and Flush Solution Additive for Sequential Mitral and Tricuspid Valve Percutaneous Edge-to-Edge Repair in a Patient With Heparin-Induced Thrombocytopenia Author links open overlay panel Zachary Colbaugh MD * , Thomas Evans Watts III MD † , Mustafa I. Ahmed MD † , Dylan R. Addis MD * ‡ § WebThe major adverse effect of heparin is heparin-induced thrombocytopenia (HIT), a paradox in which an anticoagulant causes a severe procoagulant condition due to antibodies directed against the …
Heparin-induced thrombocytopenia and cardiovascular surgery
WebThe choice of a direct thrombin inhibitors as a heparin alternative for CPB is consistent with published studies showing that the direct thrombin inhibitors hirudin, argatroban, and bivalirudin, have all been used successfully in human CPB. 16–18 Bivalirudin is currently recommended as a heparin alternative for patients with heparin-induced ... WebBivalirudin is indicated for patients with, or at risk of, heparin induced thrombocytopenia (HIT) or heparin induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing PCI. ... In clinical trials in patients undergoing PCI/PTCA, co-administration of Bivalirudin with heparin, warfarin, thrombolytics, or GPIs was associated with ... somervell county museum glen rose tx
Successful use of bivalirudin in place of heparin infusion for ...
WebAug 22, 2006 · Triggered by the immune system in response to heparin, HIT causes a low platelet count (thrombocytopenia). Two distinct types of HIT can occur: nonimmune and immune-mediated. Nonimmune HIT, … Web22. Riess FC, Pötzsch B, Bader R, et al. A case report on the use 14. Magnani HN. Heparin-induced thrombocytopenia (HIT): an of recombinant hirudin as an … WebOct 23, 2024 · Argatroban and bivalirudin are direct thrombin inhibitors (DTIs) used for the treatment of heparin-induced thrombocytopenia (HIT). The purpose of this study was to determine whether either agent offered an advantage in efficacy and ability to remain within the targeted therapeutic anticoagulation range. somerville agendas and minutes